These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 15930332)
41. Different growth patterns of non-small cell lung cancer represent distinct biologic subtypes. Sardari Nia P; Colpaert C; Vermeulen P; Weyler J; Pezzella F; Van Schil P; Van Marck E Ann Thorac Surg; 2008 Feb; 85(2):395-405. PubMed ID: 18222232 [TBL] [Abstract][Full Text] [Related]
42. [Clinical significance of cyclin Dl expression in non-small cell lung cancer]. Dworakowska D Pneumonol Alergol Pol; 2005; 73(3):297-300. PubMed ID: 16989170 [TBL] [Abstract][Full Text] [Related]
43. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions]. Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813 [TBL] [Abstract][Full Text] [Related]
44. Osteopontin expression and prognostic significance in non-small cell lung cancer. Donati V; Boldrini L; Dell'Omodarme M; Prati MC; Faviana P; Camacci T; Lucchi M; Mussi A; Santoro M; Basolo F; Fontanini G Clin Cancer Res; 2005 Sep; 11(18):6459-65. PubMed ID: 16166420 [TBL] [Abstract][Full Text] [Related]
45. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156 [TBL] [Abstract][Full Text] [Related]
46. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084 [TBL] [Abstract][Full Text] [Related]
47. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma]. Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151 [TBL] [Abstract][Full Text] [Related]
48. First clinically useful marker for lung cancer identified. Oncology (Williston Park); 2003 May; 17(5):737-8. PubMed ID: 12800797 [No Abstract] [Full Text] [Related]
49. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237 [TBL] [Abstract][Full Text] [Related]
50. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785 [TBL] [Abstract][Full Text] [Related]
51. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341 [TBL] [Abstract][Full Text] [Related]
52. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099 [TBL] [Abstract][Full Text] [Related]
53. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Kim B; Lee HJ; Choi HY; Shin Y; Nam S; Seo G; Son DS; Jo J; Kim J; Lee J; Kim J; Kim K; Lee S Cancer Res; 2007 Aug; 67(15):7431-8. PubMed ID: 17671213 [TBL] [Abstract][Full Text] [Related]
54. Cell cycle dysregulation influences survival in high risk breast cancer patients. Königsberg R; Rögelsperger O; Jäger W; Thalhammer T; Klimpfinger M; De Santis M; Hudec M; Dittrich C Cancer Invest; 2008 Aug; 26(7):734-40. PubMed ID: 18665474 [TBL] [Abstract][Full Text] [Related]
55. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Ezponda T; Pajares MJ; Agorreta J; Echeveste JI; López-Picazo JM; Torre W; Pio R; Montuenga LM Clin Cancer Res; 2010 Aug; 16(16):4113-25. PubMed ID: 20682707 [TBL] [Abstract][Full Text] [Related]
56. Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival. Fromigué O; Louis K; Dayem M; Milanini J; Pages G; Tartare-Deckert S; Ponzio G; Hofman P; Barbry P; Auberger P; Mari B Oncogene; 2003 Nov; 22(52):8487-97. PubMed ID: 14627989 [TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. Zhu CQ; Shih W; Ling CH; Tsao MS J Clin Pathol; 2006 Aug; 59(8):790-800. PubMed ID: 16873561 [TBL] [Abstract][Full Text] [Related]